These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31064370)

  • 1. Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview.
    Pouillon L; Vermeire S; Bossuyt P
    BMC Med; 2019 May; 17(1):89. PubMed ID: 31064370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease.
    Steenholdt C; Lorentsen RD; Petersen PN; Widigson ES; Kloft C; Klaasen RA; Brynskov J
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1088-1098. PubMed ID: 38380724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.
    Guidi L; Pugliese D; Panici Tonucci T; Bertani L; Costa F; Privitera G; Tolusso B; Di Mario C; Albano E; Tapete G; Gremese E; Papa A; Gasbarrini A; Rapaccini GL; Armuzzi A
    United European Gastroenterol J; 2019 Nov; 7(9):1189-1197. PubMed ID: 31700632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
    Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
    Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
    Yacoub W; Williet N; Pouillon L; Di-Bernado T; De Carvalho Bittencourt M; Nancey S; Lopez A; Paul S; Zallot C; Roblin X; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2018 Apr; 47(7):906-912. PubMed ID: 29384209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
    Dreesen E; Verstockt B; Bian S; de Bruyn M; Compernolle G; Tops S; Noman M; Van Assche G; Ferrante M; Gils A; Vermeire S
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1937-1946.e8. PubMed ID: 29704680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
    Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
    Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
    Ungaro RC; Yarur A; Jossen J; Phan BL; Chefitz E; Sehgal P; Kamal K; Bruss A; Beniwal-Patel P; Fox C; Patel A; Bahur B; Jain A; Stein D; Naik S; Dubinsky MC
    J Crohns Colitis; 2019 Aug; 13(8):963-969. PubMed ID: 31087100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease.
    Al-Bawardy B; Ramos GP; Willrich MAV; Jenkins SM; Park SH; Aniwan S; Schoenoff SA; Bruining DH; Papadakis KA; Raffals L; Tremaine WJ; Loftus EV
    Inflamm Bowel Dis; 2019 Feb; 25(3):580-586. PubMed ID: 30165638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A product review of vedolizumab in inflammatory bowel disease.
    Battat R; Dulai PS; Jairath V; Vande Casteele N
    Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months.
    Williet N; Boschetti G; Fovet M; Di Bernado T; Claudez P; Del Tedesco E; Jarlot C; Rinaldi L; Berger A; Phelip JM; Flourie B; Nancey S; Paul S; Roblin X
    Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1750-1757.e3. PubMed ID: 27890854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.
    Hanžel J; Sever N; Ferkolj I; Štabuc B; Smrekar N; Kurent T; Koželj M; Novak G; Compernolle G; Tops S; Gils A; Drobne D
    United European Gastroenterol J; 2019 Jul; 7(6):741-749. PubMed ID: 31316778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.
    D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
    Immunotherapy; 2019 May; 11(7):565-575. PubMed ID: 30860423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients.
    Schulze H; Esters P; Hartmann F; Stein J; Christ C; Zorn M; Dignass A
    Scand J Gastroenterol; 2018 Jun; 53(6):670-676. PubMed ID: 29560811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
    Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
    J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
    J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.
    Yarur AJ; Deepak P; Vande Casteele N; Battat R; Jain A; Okada L; Osterman M; Regueiro M
    Dig Dis Sci; 2021 Oct; 66(10):3563-3569. PubMed ID: 33089483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.